Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales

Overview

• Biopharmaceutical firm's Q2 product revenue rose 55% yr/yr, driven by ARCALYST sales growth

• Q2 net income increased to $25.4 mln from $17.8 mln a year earlier

• Company raised 2026 ARCALYST net product revenue guidance to $980-$995 mln

Outlook

• Kiniksa raises 2026 ARCALYST net product revenue guidance to $980-$995 mln

• Company expects current operating plan to remain cash flow positive on an annual basis

• Kiniksa expects to initiate KPL-1161 Phase 1 trial by end of 2026

Result Drivers

• ARCALYST PRESCRIBER GROWTH - Co said growth in new and repeat prescribers of ARCALYST in recurrent pericarditis led to a meaningful increase in patients on therapy

• OPERATING EXPENSES - Co said higher operating expenses were mainly due to increased costs from ARCALYST sales, collaboration expenses, and investment in clinical and preclinical development

Company press release: ID:nGNX5P1vJ

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International, PLC is $72.00, about 13.3% above its July 27 closing price of $63.54

• The stock recently traded at 42 times the next 12-month earnings vs. a P/E of 40 three months ago

Reuters Recommended Reads

• July 28 - Incyte beats Q2 revenue estimates on strong product demand

• July 27 - Argenx to buy Forte Biosciences for about $2.2 billion

• July 27 - AstraZeneca profit beat, bullish tone ease worries over drug pipeline

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)